BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29480373)

  • 1. Molecular docking, molecular modeling, and molecular dynamics studies of azaisoflavone as dual COX-2 inhibitors and TP receptor antagonists.
    Hadianawala M; Mahapatra AD; Yadav JK; Datta B
    J Mol Model; 2018 Feb; 24(3):69. PubMed ID: 29480373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro pharmacological evaluation of multitarget agents for thromboxane prostanoid receptor antagonism and COX-2 inhibition.
    Hoxha M; Buccellati C; Capra V; Garella D; Cena C; Rolando B; Fruttero R; Carnevali S; Sala A; Rovati GE; Bertinaria M
    Pharmacol Res; 2016 Jan; 103():132-43. PubMed ID: 26621246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions of selected indole derivatives with COX-2 and their in silico structure modifications towards the development of novel NSAIDs.
    Dileep KV; Remya C; Tintu I; Sadasivan C
    J Biomol Struct Dyn; 2014; 32(11):1855-63. PubMed ID: 24053423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lead compound design for TPR/COX dual inhibition.
    Krishna A; Yadav A
    J Mol Model; 2012 Sep; 18(9):4397-408. PubMed ID: 22588583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of COX-2 inhibitors via structure-based virtual screening and molecular dynamics simulation.
    Razzaghi-Asl N; Mirzayi S; Mahnam K; Sepehri S
    J Mol Graph Model; 2018 Aug; 83():138-152. PubMed ID: 29936228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.
    Egan KM; Wang M; Fries S; Lucitt MB; Zukas AM; Puré E; Lawson JA; FitzGerald GA
    Circulation; 2005 Jan; 111(3):334-42. PubMed ID: 15655126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antagonism of thromboxane receptors by diclofenac and lumiracoxib.
    Selg E; Buccellati C; Andersson M; Rovati GE; Ezinga M; Sala A; Larsson AK; Ambrosio M; Låstbom L; Capra V; Dahlén B; Ryrfeldt A; Folco GC; Dahlén SE
    Br J Pharmacol; 2007 Dec; 152(8):1185-95. PubMed ID: 17965743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome wide analysis and comparative docking studies of new diaryl furan derivatives against human cyclooxygenase-2, lipoxygenase, thromboxane synthase and prostacyclin synthase enzymes involved in inflammatory pathway.
    Sekhar PN; Reddy LA; De Maeyer M; Kumar KP; Srinivasulu YS; Sunitha MS; Sphoorthi IS; Jayasree G; Rao AM; Kothekar VS; Narayana PV; Kishor PB
    J Mol Graph Model; 2009 Nov; 28(4):313-29. PubMed ID: 19766029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The study of dual COX-2/5-LOX inhibitors by using electronic-topological approach based on data on the ligand-receptor interactions.
    Aksakal F; Shvets N; Dimoglo A
    J Mol Graph Model; 2015 Jul; 60():79-88. PubMed ID: 26117823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deciphering the mechanism behind the varied binding activities of COXIBs through Molecular Dynamic Simulations, MM-PBSA binding energy calculations and per-residue energy decomposition studies.
    Chaudhary N; Aparoy P
    J Biomol Struct Dyn; 2017 Mar; 35(4):868-882. PubMed ID: 26982261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The bitter barricading of prostaglandin biosynthesis pathway: understanding the molecular mechanism of selective cyclooxygenase-2 inhibition by amarogentin, a secoiridoid glycoside from Swertia chirayita.
    Shukla S; Bafna K; Sundar D; Thorat SS
    PLoS One; 2014; 9(6):e90637. PubMed ID: 24603686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural Probing, Screening and Structure-Based Drug Repositioning Insights into the Identification of Potential Cox-2 Inhibitors from Selective Coxibs.
    Bommu UD; Konidala KK; Pamanji R; Yeguvapalli S
    Interdiscip Sci; 2019 Jun; 11(2):153-169. PubMed ID: 29236213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular modeling, synthesis and screening of some new 4-thiazolidinone derivatives with promising selective COX-2 inhibitory activity.
    Unsal-Tan O; Ozadali K; Piskin K; Balkan A
    Eur J Med Chem; 2012 Nov; 57():59-64. PubMed ID: 23047224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Known compounds and new lessons: structural and electronic basis of flavonoid-based bioactivities.
    Meshram RJ; Bagul KT; Pawnikar SP; Barage SH; Kolte BS; Gacche RN
    J Biomol Struct Dyn; 2020 Mar; 38(4):1168-1184. PubMed ID: 30898030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular design, synthesis and biological evaluation of cyclic imides bearing benzenesulfonamide fragment as potential COX-2 inhibitors. Part 2.
    Al-Suwaidan IA; Alanazi AM; El-Azab AS; Al-Obaid AM; ElTahir KE; Maarouf AR; Abu El-Enin MA; Abdel-Aziz AA
    Bioorg Med Chem Lett; 2013 May; 23(9):2601-5. PubMed ID: 23528298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of new indomethacin-based analogs with potentially selective cyclooxygenase-2 inhibition and observed diminishing to PGE2 activities.
    Kassab SE; Khedr MA; Ali HI; Abdalla MM
    Eur J Med Chem; 2017 Dec; 141():306-321. PubMed ID: 29031075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural modeling and simulation studies of human cyclooxygenase (COX) isozymes with selected terpenes: implications in drug designing and development.
    Singh S; Pandey VP; Naaz H; Singh P; Dwivedi UN
    Comput Biol Med; 2013 Jul; 43(6):744-50. PubMed ID: 23668350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, biological evaluation and molecular modeling of dihydro-pyrazolyl-thiazolinone derivatives as potential COX-2 inhibitors.
    Qiu KM; Yan R; Xing M; Wang HH; Cui HE; Gong HB; Zhu HL
    Bioorg Med Chem; 2012 Nov; 20(22):6648-54. PubMed ID: 23062711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, anti-inflammatory, analgesic, COX1/2-inhibitory activity, and molecular docking studies of hybrid pyrazole analogues.
    Alam MJ; Alam O; Khan SA; Naim MJ; Islamuddin M; Deora GS
    Drug Des Devel Ther; 2016; 10():3529-3543. PubMed ID: 27826185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies of the benzopyran class of selective COX-2 inhibitors using 3D-QSAR and molecular docking.
    Yadav DK; Saloni ; Sharma P; Misra S; Singh H; Mancera RL; Kim K; Jang C; Kim MH; Pérez-Sánchez H; Choi EH; Kumar S
    Arch Pharm Res; 2018 Dec; 41(12):1178-1189. PubMed ID: 28822076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.